Human, an Australian predictive healthcare startup, has raised $46 million in funding led by Airtree Ventures, with growth equity firm Left Lane Capital also backing the round, according to Airtree Ventures.

The platform pools clinical data from doctors, researchers, and patients to identify which treatments produce the best outcomes at scale. Rather than waiting years for randomised controlled trials — the gold-standard research method — to produce guidelines, Human aims to show what is actually working in practice, tailored to individual patient profiles. This differs meaningfully from the electronic health record (EHR) vendors and insurance claims databases that typically dominate health IT funding.

The investor lineup signals confidence on two fronts. Airtree is among Australia's most active growth-stage funds, with a strong track record backing enterprise software and deep tech. Left Lane Capital, based in New York, has focused its healthcare bets on businesses with durable customer retention and network effects — the kind of platforms where value compounds as data volumes grow. Both firms backing the same round suggests conviction in both the domestic opportunity and a plausible international path.

At $46 million, this raise sits in the Series A or Series B range for Australian tech, though the exact round type has not been publicly confirmed. For scale: the median Series B in Australian tech has typically landed between $15 and $30 million. A raise this size likely reflects either a later-stage primary round or a larger-than-typical earlier one, pointing to the cost of building and validating a clinical-grade data platform.

The health tech funding landscape has shifted considerably since the 2021–2022 peak and subsequent downturn. Growth equity and late-seed rounds have survived, but primarily for companies with defensible data assets and a clear regulatory path forward. A raise of this size in 2026, backed by institutional names, signals that Human has passed the initial diligence threshold on both fronts.

Where most predictive health platforms have historically stumbled is the gap between observational data and actionable clinical guidance. Aggregating what doctors and patients report as effective is not the same as building the controlled evidence base hospitals and practitioners need to justify switching systems. Whether Human has a credible answer to that problem — one hospitals would actually adopt — is not settled by the funding announcement.

What the capital does confirm is that Human now has meaningful runway to answer that question. Forty-six million dollars buys time in a capital-intensive sector: negotiating data partnerships, engaging regulators, and conducting the validation studies required to persuade hospital procurement committees. How the company deploys that capital — whether it pursues depth in the Australian market first or pushes internationally early — will shape what happens next.